Two-decade Pfizer mission pays off for Guggenheim's deal king


LONDON/NEW YORK Alan Schwartz knows how to play a long game. The executive chairman of boutique investment bank Guggenheim Partners spent almost 20 years cultivating Pfizer boss Ian Read as a client. His strategy paid off handsomely when Guggenheim was named lead adviser for one of the biggest deals in history - Viagra-maker Pfizer's $160 billion acquisition of Botox-maker Allergan .

Any Imperial Tobacco takeover would face major hurdles 4:34pm GMT

LONDON Britain's Imperial Tobacco has been the object of intensifying takeover speculation, but hopes of a deal for the maker of Gauloises and Davidoff cigarettes could be snuffed out by the huge complications facing any bidder.


Merck plans to sell its allergy business unit to cut debt: Bloomberg 10:32pm GMT

German drugs and chemicals maker Merck KGaA is planning to sell its allergy business, Allergopharma, Bloomberg reported, citing sources.


Bidders sound out Bang & Olufsen about takeover 2:57pm GMT

COPENHAGEN Danish high-end stereo and TV maker Bang & Olufsen said it had received approaches regarding a potential takeover offer, sending its shares soaring by more than 30 percent.


Alibaba in talks with Hong Kong's SCMP Group for media assets: source 9:54am GMT

SHANGHAI/HONG KONG Chinese e-commerce titan Alibaba Group Holding Ltd has approached the publisher of Hong Kong's South China Morning Post newspaper to discuss buying its media assets, a source familiar with the matter said on Thursday. | Video


NXP wins U.S. antitrust approval to buy Freescale Semiconductor 25 Nov 2015

WASHINGTON NXP Semiconductors N.V. has won U.S. antitrust approval to buy Freescale Semiconductor Ltd, a deal worth $11.8 billion, on condition that it sell its radio frequency power business, the Federal Trade Commission said on Wednesday.


China's chip crusade to intensify sector's record M&A run 25 Nov 2015

TAIPEI/TOKYO China's unabashed interest in foreign chipmakers in an already record year of deals has been quickly read by rivals as a sign that mergers and acquisitions (M&As) will get more competitive and target companies will get more expensive.


Ball offers EU to sell 11 plants for Rexam deal approval: sources 25 Nov 2015

BRUSSELS/NEW YORK U.S. drinks can maker Ball Corp is ready to sell 11 European plants to get EU antitrust regulators to approve its 4.43 billion pound ($6.69 billion) acquisition of Britain's Rexam Plc, people familiar with the matter said.


Petco’s buyout financing joins $14 billion U.S. leveraged loan pipeline 25 Nov 2015

NEW YORK A debt financing of around US$3bn backing CVC Capital Partners and the Canada Pension Plan Investment Board’s US$4.6bn acquisition of Petco Animal Supplies is joining a US$14bn pipeline of US leveraged buyout loans that are waiting to be sold after a US$5.5bn deal for data storage provider Veritas was pulled last week.

From Our Partners